NewsALNYLAMThursday, February 5, 2026 · February 5, 2026
Alnylam Reports Record $2.8B Revenue from RNAi Portfolio
WHY IT MATTERS
RNAi platform proving commercially viable for rare diseases.
Alnylam reported $2.8 billion from RNA interference therapies for hereditary ATTR and other rare diseases.
Related conditions
Related news
FDA
FDA Approves XTORO
XTORO (FINAFLOXACIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…
FDA
FDA Approves SABRIL
SABRIL (VIGABATRIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…